Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data suggests … Read more
NEW YORK — Wastewater testing does a good job at detecting mpox infections, U.S. health officials said in a report Thursday that bolsters a push to use sewage to track more diseases. U.S. Centers for Disease Control and Prevention researchers found that over the course of a week, there was a 32% likelihood the tests … Read more
Descrease article font size Increase article font size Health Canada on Thursday approved another respiratory syncytial virus (RSV) vaccine for adults over the age of 60 and pregnant people. Pfizer’s bivalent RSV vaccine, Abrysvo, has been authorized for the use of pregnant individuals from 32 through 36 weeks gestational age for the prevention of lower respiratory … Read more
